187. Kabuki syndrome Clinical trials / Disease details
Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03855631 (ClinicalTrials.gov) | September 28, 2020 | 22/2/2019 | Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders | Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders | Kabuki Syndrome 1 | Genetic: Intervention on primary cultured cells | University Hospital, Montpellier | Association Française contre les Myopathies Telethon | Completed | 6 Years | N/A | All | 8 | France |